Clinical trials: Pancreatic Metastasis
Advanced Metastatic Pancreatic Cancer
Nal-IRI/5-FU/LV Chemotherapy Combined With PD-L1 Inhibitor and Multi-target Anti-angiogenic Small Molecule±SBRT as Second-line Therapy in Metastatic Pancreatic Cancer Patients
This study is a single-arm, multi-center, multi-cohort, prospective clinical study initiated by the investigator. The indication of this study is: patients with advanced metastatic pancreatic cancer who have progressed after…
- Trial name
- NCT06662006
- Testing
- nal-IRI,5-fu,LV, benmelstobart, anlotinib
- Where
- China
- Volunteers
- 56 people
- Sponsor
- The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School
Pancreatic Carcinoma
A Clinical Trial to Evaluate Tolerability and Security of TQB2858 Injection in Subjects With Advanced Pancreatic Carcinoma
This study is divided into three phases: single-dose exploration, combination dosage exploration and cohort expansion. The Single-dose exploration stage aims to evaluate the tolerability of TQB2858 injection in subjects with…
- Trial name
- NCT05193604
- Testing
- TQB2858 injection, Anlotinib Hydrochloride Capsule, Gemcitabine hydrochloride for injection
- Where
- China
- Volunteers
- 29 people
- Sponsor
- Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Metastatic Pancreatic Cancer
A Safety and Efficacy Study of RX-0201 Plus Gemcitabine in Metastatic Pancreatic Cancer
To assess the safety and efficacy of a combined therapy regimen of RX-0201 plus Gemcitabine, in subjects with metastatic pancreatic cancer.
- Trial name
- NCT01028495
- Testing
- RX-0201 plus Gemcitabine
- Where
- 10 sites in United States, India
- Volunteers
- 31 people
- Sponsor
- Rexahn Pharmaceuticals, Inc.
Metastatic Cancer, Metastatic Colorectal Cancer
Study of OB-002 in Patients With Refractory Metastatic Cancer
This is an open-label, non-randomized trial with OB-002 monotherapy dose escalation followed by a dose expansion in patients with metastatic colorectal, pancreatic, gastric, breast, or urothelial cancer who have progressed on two…
- Conditions
- Metastatic Cancer, Metastatic Colorectal Cancer, Metastatic Pancreatic Cancer, Metastatic Gastric Cancer
- Trial name
- NCT05940844
- Testing
- OB-002
- Sponsor
- Orion Biotechnology Polska Sp. z o.o.
Pancreatic Cancer, Microbial Colonization
Gut Microbiota and Metabolite Signatures Associated With Lymph Node Metastasis in Pancreatic Cancer
This study investigates the association between gut microbiota and lymph node metastasis (LNM) in pancreatic cancer. While gut microbial dysbiosis has been linked to pancreatic cancer development and distant metastasis, its role…
- Conditions
- Pancreatic Cancer, Microbial Colonization, Lymph Node Metastasis
- Trial name
- NCT07161921
- Testing
- lymph node metastasis
- Where
- China
- Volunteers
- 55 people
- Sponsor
- Peking Union Medical College Hospital
Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer
QUILT-2.019: A Study of AMG 655 or AMG 479 in Combination With Gemcitabine for Treatment of Metastatic Pancreatic Cancer
This is a multi-center, 2-part study of AMG 655, AMG 479 or AMG 655-placebo plus gemcitabine as first-line treatment of subjects with metastatic pancreatic cancer.
- Conditions
- Adenocarcinoma of the Pancreas, Metastatic Pancreatic Cancer, Pancreatic Cancer
- Trial name
- NCT00630552
- Testing
- AMG 479, AMG 655
- Where
- 44 sites in United States
- Volunteers
- 138 people
- Sponsor
- NantCell, Inc.
Melanoma Stage IV, Sarcoma
Heat Shock Protein (HSP) 70 to Quantify and Characterize Circulating Tumor Cells
This study investigates the ability of heat shock protein HSP70 to isolate and quantify circulating tumor cells (CTCs) in patients with advanced or metastatic tumors.
- Conditions
- Melanoma Stage IV, Sarcoma, Squamous Cell Carcinoma, Pancreatic Cancer Stage IV
- Trial name
- HSP70CTC (NCT04628806)
- Testing
- CTC isolation by HSP70
- Where
- Germany
- Volunteers
- 120 people
- Sponsor
- Charite University, Berlin, Germany
Metastatic Pancreatic Cancer, NSCLC, Metastatic
Patient Reported Outcomes Registry in Patient With Cancer Cachexia
Evaluation of patient reported outcomes (PRO) with tumor cachexia in a real life setting.
- Trial name
- PROXie (NCT02983500)
- Where
- Germany
- Volunteers
- 253 people
- Sponsor
- iOMEDICO AG
Advanced Solid Tumor, Metastatic Breast Cancer
A Phase 1 Trial of ERX-315 in Participants With Advanced Solid Tumors
This is a Phase 1 study to assess the safety of ERX-315 in patients with advanced solid tumors that have failed approved systemic therapies.
- Conditions
- Advanced Solid Tumor, Metastatic Breast Cancer, Metastatic Ovarian Cancer, Metastatic Endometrial Cancer
- Trial name
- NCT06533332
- Testing
- ERX-315
- Where
- 5 sites in Australia
- Volunteers
- 36 people
- Sponsor
- EtiraRx Australia Pty Ltd
Pancreatitis, Chronic, Stricture; Bile Duct
GORE® VIABIL® Biliary Endoprosthesis in the Treatment of Benign Biliary Strictures Secondary to Chronic Pancreatitis
This study will evaluate the safety and effectiveness of the GORE® VIABIL® Biliary Endoprosthesis in the treatment of benign biliary strictures secondary to Chronic Pancreatitis (CP).
- Trial name
- VIABILITY (NCT05820009)
- Testing
- GORE® VIABIL® Biliary Endoprosthesis, GORE® VIABIL® Short Wire Biliary Endoprosthesis
- Where
- 2 sites in United States
- Volunteers
- 133 people
- Sponsor
- W.L.Gore & Associates
Pancreatic Ductal Adenocarcinoma
A Study Comparing Navlimetostat (BMS-986504) in Combination With Nab-paclitaxel and Gemcitabine Versus Placebo in Combination With Nab-paclitaxel and Gemcitabine in Participants With Untreated Metastatic Pancreatic Ductal Adenocarcinoma With Homozygous MTAP Deletion (MountainTAP-30)
The purpose of this study is to assess the safety and efficacy of Navlimetostat (BMS-986504), a selective, MTA-cooperative PRMT5 inhibitor, in combination with Nab-paclitaxel/Gemcitabine (nab-p/gem) versus placebo in combination…
- Trial name
- NCT07076121
- Testing
- Navlimetostat, Gemcitabine, Nab-paclitaxel
- Where
- 269 sites in United States, Argentina and 34 more
- Volunteers
- 470 people
- Sponsor
- Bristol-Myers Squibb
Melanoma, Cervical Carcinoma
A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors
This is a Phase 1, multiple dose, ascending-dose escalation study and expansion study designed to define a maximum tolerated dose and/or recommended dose of XmAb22841 monotherapy and in combination with pembrolizumab; to assess…
- Conditions
- Melanoma, Cervical Carcinoma, Pancreatic Carcinoma, Triple Negative Breast Cancer
- Trial name
- DUET-4 (NCT03849469)
- Testing
- XmAb®22841, Pembrolizumab (Keytruda®)
- Where
- 28 sites in United States
- Volunteers
- 78 people
- Sponsor
- Xencor, Inc.
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Pancreatic Cancer
Safety and Efficacy of G17DT Immunogen Combined With Gemcitabine vs. Gemcitabine in the Treatment of Advanced Pancreatic Carcinoma
This study will test whether the G17DT Immunogen, when administered in combination with chemotherapy, is an effective and safe treatment for pancreatic cancer.
- Trial name
- NCT00044031
- Testing
- G17DT Immunogen
- Volunteers
- 394 people
- Sponsor
- Cancer Advances Inc.
Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas
Dynamic Contrast Enhanced MRI in Patients With Advanced Breast or Pancreatic Cancer With Metastases to the Liver or Lung
This phase I trial studies the side effects of dynamic contrast enhanced magnetic resonance imaging (DCE-MRI) in patients with advanced breast or pancreatic cancer with metastases to the liver or lung.
- Conditions
- Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Liver Metastases, Lung Metastases
- Trial name
- NCT01741597
- Testing
- dynamic contrast-enhanced magnetic resonance imaging, pharmacological study, tumor-homing peptide iRGD
- Where
- United States
- Sponsor
- City of Hope Medical Center
Pancreatic Cancer
Study of Gemcitabine and Erlotinib Plus Sorafenib (GES) in Metastatic Pancreatic Cancer
This study tests the combination of two targeted therapies,along with chemotherapy treatment in the treatment of pancreatic cancer.
- Trial name
- NCT00696696
- Testing
- Gemcitabine, Erlotinib, Sorafenib
- Where
- 3 sites in United States
- Volunteers
- 45 people
- Sponsor
- NYU Langone Health
Neoplasm
PTK787 in Patients With Advanced Metastatic Pancreatic Adenocarcinoma
The purpose of this research study is to find out if an experimental drug called PTK787/ZK222584 might be effective against advanced or metastatic pancreatic cancer.
- Trial name
- NCT00226005
- Testing
- PTK787/ZK222584
- Where
- 7 sites in United States
- Volunteers
- 67 people
- Sponsor
- Pancreatic Cancer Research Team
Kidney Cancer, Head and Neck Cancer
177Lu-J591 Antibody in Patients With Nonprostate Metastatic Solid Tumors
The purpose of this study is to evaluate changes in tumor blood flow and disease response to the investigation agent, 177Lu-J591.
- Conditions
- Kidney Cancer, Head and Neck Cancer, Breast Cancer, Non-small Cell Lung Cancer
- Trial name
- NCT00967577
- Testing
- 177Lu-J591
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Weill Medical College of Cornell University
Pancreatic Neoplasm
Aflibercept Compared to Placebo in Term of Efficacy in Patients Treated With Gemcitabine for Metastatic Pancreatic Cancer
The main objective of the study was to evaluate the effectiveness of aflibercept treatment by comparison to placebo in increasing the overall survival (OS) in participants with metastatic pancreatic cancer, treated with…
- Trial name
- VANILLA (NCT00574275)
- Testing
- Aflibercept (ziv-aflibercept, AVE0005, VEGF trap, ZALTRAP®), Gemcitabine
- Where
- 24 sites in United States, Argentina and 22 more
- Volunteers
- 546 people
- Sponsor
- Sanofi
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.